---
title: Lipid-Lowering Drugs
type: content
phase: 1
status: complete
priority: high
tags: [lipid-lowering, statins, fibrates, PCSK9-inhibitors, ezetimibe, niacin, cholesterol, triglycerides, atherosclerosis]
created: 2025-11-08
last_modified: 2025-11-08
---

# Lipid-Lowering Drugs

## Introduction

Dyslipidemia is a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Lipid-lowering therapy, particularly statins, has been proven to reduce cardiovascular morbidity and mortality. Understanding lipid metabolism and the mechanisms of lipid-lowering drugs is essential for cardiovascular risk reduction.

## Core Concept

**Lipoproteins transport lipids in blood**:
- **Chylomicrons**: Transport dietary triglycerides from intestine
- **VLDL**: Transport endogenous triglycerides from liver
- **LDL**: Deliver cholesterol to tissues ("bad cholesterol")
- **HDL**: Reverse cholesterol transport from tissues to liver ("good cholesterol")

**Atherogenic lipids**: LDL-C, VLDL, remnants
**Protective**: HDL-C

**Therapeutic goals**:
- ↓LDL cholesterol (primary target)
- ↓Triglycerides (if elevated)
- ↑HDL cholesterol (beneficial but not primary target)

---

## Statins (HMG-CoA Reductase Inhibitors)

### Mechanism of Action

**Primary Mechanism**:
- Competitively inhibit **HMG-CoA reductase** (rate-limiting enzyme in cholesterol synthesis)
- ↓Hepatic cholesterol synthesis
- ↑Hepatic LDL receptors (compensatory response)
- ↑LDL clearance from blood
- **Net result: ↓LDL-C** (25-55%)

**Pleiotropic Effects** (cholesterol-independent):
- ↓Inflammation (↓CRP)
- Improve endothelial function
- Stabilize atherosclerotic plaques
- Antithrombotic effects
- ↓Oxidative stress

### Drug Examples

**Lipophilic** (cross BBB, more extrahepatic effects):
- **Atorvastatin** (Lipitor): High potency, long t½ (14 hr)
- **Simvastatin**: Moderate potency, prodrug
- **Lovastatin**: Lower potency, prodrug
- **Fluvastatin**: Lower potency

**Hydrophilic** (liver-selective):
- **Rosuvastatin** (Crestor): High potency, long t½ (19 hr)
- **Pravastatin**: Moderate potency

**Potency Ranking** (LDL reduction):
1. **Rosuvastatin** (strongest)
2. **Atorvastatin**
3. **Pitavastatin**
4. **Simvastatin**
5. **Lovastatin, Pravastatin, Fluvastatin** (weakest)

### Pharmacokinetics

**Absorption**: Well absorbed orally
**Metabolism**:
- Most: Hepatic CYP3A4 (atorvastatin, simvastatin, lovastatin)
- Rosuvastatin, pravastatin: Minimal CYP metabolism
- Fluvastatin: CYP2C9

**Excretion**:
- Primarily biliary
- Minimal renal (except rosuvastatin, pravastatin ~30%)

**Timing**:
- **Short-acting** (simvastatin, lovastatin): Evening dosing (cholesterol synthesis ↑ at night)
- **Long-acting** (atorvastatin, rosuvastatin): Any time of day

### Clinical Indications

**Primary Prevention**:
- Age 40-75 + diabetes
- Age 40-75 + LDL ≥70 mg/dL + 10-year ASCVD risk ≥7.5%
- LDL ≥190 mg/dL

**Secondary Prevention**:
- Established ASCVD (MI, stroke, PAD, stable angina)
- High-intensity statin recommended

**Other Indications**:
- Familial hypercholesterolemia
- CKD

### Dosing and Intensity

**High-Intensity** (↓LDL ≥50%):
- Atorvastatin 40-80 mg
- Rosuvastatin 20-40 mg

**Moderate-Intensity** (↓LDL 30-49%):
- Atorvastatin 10-20 mg
- Rosuvastatin 5-10 mg
- Simvastatin 20-40 mg
- Pravastatin 40-80 mg
- Lovastatin 40 mg
- Fluvastatin 80 mg
- Pitavastatin 1-4 mg

**Low-Intensity** (↓LDL <30%):
- Simvastatin 10 mg
- Pravastatin 10-20 mg
- Lovastatin 20 mg
- Fluvastatin 20-40 mg

### Lipid Effects

- **LDL-C**: ↓25-55% (dose and drug dependent)
- **Triglycerides**: ↓10-30%
- **HDL-C**: ↑5-15%

**Clinical Benefit**:
- ↓Cardiovascular events ~25-35%
- ↓All-cause mortality ~10%
- ↓Stroke ~20%
- Benefits increase with LDL reduction

### Adverse Effects

**Common**:
- **Myalgias** (5-10%): Muscle aches without CK elevation
  - Most common reason for discontinuation
  - May be nocebo effect in some cases
  - Try different statin or alternate-day dosing

**Serious**:

**Myopathy/Rhabdomyolysis** (0.1-0.5%):
- Muscle pain + ↑CK (>10× ULN)
- Rhabdomyolysis: Severe muscle breakdown, myoglobinuria, renal failure
- **Risk factors**:
  - High-dose statins (especially simvastatin >40 mg)
  - Drug interactions (CYP3A4 inhibitors)
  - Hypothyroidism
  - Renal impairment
  - Asian ancestry (rosuvastatin)
  - Fibrate combination (especially gemfibrozil)
  - Age >80
  - Small body frame

**Hepatotoxicity** (0.5-2%):
- ↑Transaminases (ALT/AST)
- Usually asymptomatic, reversible
- Monitor: Baseline LFTs; repeat if symptoms
- Stop if ALT >3× ULN or symptoms

**New-Onset Diabetes** (9-13%):
- Slight increase in diabetes risk (0.1-0.2% absolute increase)
- **Benefits far outweigh risk**
- Higher risk with: High-dose, intensive therapy

**Cognitive Effects**:
- Controversial; large trials show no significant cognitive decline
- FDA warning based on case reports

**Hemorrhagic Stroke**:
- Slight increase in very high-intensity therapy
- Overall stroke reduction

**Drug Interactions**:

**CYP3A4 Inhibitors** (↑statin levels, ↑myopathy risk):
- Azole antifungals (itraconazole, ketoconazole)
- Macrolide antibiotics (clarithromycin, erythromycin)
- HIV protease inhibitors
- **Grapefruit juice** (large amounts)
- Diltiazem, verapamil
- Amiodarone

**Strategies**:
- Use non-CYP3A4 statins (rosuvastatin, pravastatin, fluvastatin)
- Reduce dose
- Avoid combination

**Fibrates**:
- **Gemfibrozil**: Avoid combination (↑statin levels, ↑myopathy)
- **Fenofibrate**: Safer combination if needed

**Digoxin**: ↑Digoxin levels

**Warfarin**: ↑INR (monitor closely)

### Contraindications

**Absolute**:
- Active liver disease
- Pregnancy (Category X)
- Breastfeeding

**Relative**:
- History of statin-induced myopathy
- Unexplained persistent ↑transaminases

### Monitoring

**Before Starting**:
- Lipid panel (fasting)
- LFTs (baseline)
- Consider CK (if high risk for myopathy)

**After Starting**:
- **No routine CK or LFT monitoring** (per guidelines)
- Monitor for symptoms (muscle pain, weakness, dark urine, fatigue)
- Check LFTs if symptoms develop
- Lipid panel: 4-12 weeks, then periodically

**2018 AHA/ACC Guidelines**:
- Focus on **statin intensity** rather than specific LDL targets
- Check lipids to assess adherence and response

### Special Populations

**Elderly (>75)**:
- Start low, titrate slowly
- Higher myopathy risk
- Consider moderate-intensity

**Renal Impairment**:
- Most statins safe (dose-adjust rosuvastatin, pravastatin)
- Avoid high-dose

**Asian Ancestry**:
- Rosuvastatin: Start lower dose (5 mg)
- Higher systemic exposure

### Clinical Pearls

1. **First-line for ASCVD prevention**: Proven mortality benefit
2. **High-intensity for secondary prevention**: Atorvastatin 40-80 mg or rosuvastatin 20-40 mg
3. **Myalgias common**: Try different statin, alternate-day dosing, CoQ10 (limited evidence)
4. **LDL reduction**: Each 40 mg/dL ↓LDL → ~20% ↓CV events
5. **Avoid simvastatin >40 mg**: ↑Myopathy risk
6. **Drug interactions**: Key with CYP3A4 metabolized statins
7. **No need for "drug holidays"**: Benefits accrue with continuous use
8. **Diabetes risk**: Small increase acceptable given CV benefits
9. **Atorvastatin, rosuvastatin**: Most potent, any-time dosing
10. **Pregnancy**: Absolutely contraindicated

---

## Ezetimibe (Zetia)

### Mechanism of Action

- Inhibits **Niemann-Pick C1-Like 1 (NPC1L1) protein**
- Located on intestinal brush border
- Blocks cholesterol absorption from intestine
- ↓Delivery of dietary and biliary cholesterol to liver
- ↑Hepatic LDL receptors (compensatory)
- **↓LDL-C ~15-20%**

### Pharmacokinetics

- Oral administration
- Extensively glucuronidated
- Enterohepatic recirculation
- Biliary excretion
- t½ = 22 hours
- No significant CYP metabolism (few drug interactions)

### Clinical Indications

1. **Combination with statin** (when statin alone insufficient)
2. **Statin intolerance** (monotherapy)
3. **Familial hypercholesterolemia** (with statin)

### Efficacy

**Monotherapy**:
- ↓LDL-C: 15-20%
- Minimal effect on TG, HDL

**With Statin** (additive):
- ↓LDL-C: Additional 15-20%
- Atorvastatin 10 mg + ezetimibe ≈ atorvastatin 80 mg (LDL reduction)

**Outcomes**:
- **IMPROVE-IT trial**: Ezetimibe + simvastatin vs. simvastatin alone
  - ↓CV events by 6.4% (absolute) in ACS patients
  - Modest but significant benefit

### Adverse Effects

- Very well tolerated
- Diarrhea, abdominal pain (uncommon)
- ↑Transaminases (rare, especially with statin)
- Myalgias (rare as monotherapy)

### Drug Interactions

- **Fibrates**: May ↓ezetimibe efficacy (blocks gallbladder reabsorption)
- **Cyclosporine**: ↑Ezetimibe levels
- Minimal other interactions (advantage over statins)

### Clinical Pearls

1. **Add to statin**: When LDL goal not reached
2. **Alternative to high-dose statin**: E.g., atorvastatin 10 + ezetimibe vs. atorvastatin 80
3. **Well-tolerated**: Option in statin intolerance
4. **Fixed-dose combinations** available (e.g., Vytorin = simvastatin + ezetimibe)
5. **Pregnancy Category C**: Avoid

---

## PCSK9 Inhibitors

### Mechanism of Action

**Background**:
- **PCSK9** (Proprotein Convertase Subtilisin/Kexin type 9) promotes degradation of LDL receptors
- ↓PCSK9 → ↑LDL receptors → ↑LDL clearance → ↓LDL-C

**Drugs (Monoclonal Antibodies)**:
- **Evolocumab** (Repatha)
- **Alirocumab** (Praluent)

**Mechanism**:
- Bind and inhibit PCSK9
- ↑Hepatic LDL receptors
- **↓LDL-C 50-70%** (dramatic reduction)

### Pharmacokinetics

- **Subcutaneous injection** (every 2-4 weeks)
- Monoclonal antibodies
- Degraded by proteolysis
- Not metabolized by liver or kidneys
- t½ = 11-20 days

### Clinical Indications

**FDA-Approved**:
1. **Heterozygous familial hypercholesterolemia**
2. **Clinical ASCVD** requiring additional LDL lowering
3. **Homozygous familial hypercholesterolemia**

**Typically Used When**:
- LDL ≥70 mg/dL on maximally tolerated statin + ezetimibe
- Statin intolerance
- Very high cardiovascular risk

### Efficacy

- **LDL-C reduction**: 50-70%
- Can achieve LDL <50 mg/dL or even <30 mg/dL
- **Cardiovascular outcomes**:
  - **FOURIER trial** (evolocumab): ↓CV events 15% (absolute 1.5%)
  - **ODYSSEY OUTCOMES** (alirocumab): ↓CV events 15%

### Adverse Effects

- **Generally well-tolerated**
- Injection site reactions (common, mild)
- Flu-like symptoms
- Myalgias (rare)
- Neurocognitive effects (not confirmed in trials)
- No hepatotoxicity

### Dosing

**Evolocumab**:
- 140 mg SC every 2 weeks OR
- 420 mg SC monthly

**Alirocumab**:
- 75-150 mg SC every 2 weeks

### Cost and Access

- **Very expensive**: $5,000-14,000/year
- Insurance often requires:
  - Trial of statin + ezetimibe
  - LDL >100 mg/dL (varies)
  - Documented ASCVD or FH
- Cost-effectiveness debated

### Clinical Pearls

1. **Most potent LDL-lowering**: 50-70% reduction
2. **CV outcome benefit proven**: FOURIER and ODYSSEY trials
3. **Well-tolerated**: Alternative in statin intolerance
4. **Injection every 2-4 weeks**: Adherence consideration
5. **Very expensive**: Limited by cost and insurance
6. **Reserved for high-risk patients**: On max statin + ezetimibe with LDL still elevated

---

## Fibrates (Fibric Acid Derivatives)

### Mechanism of Action

- **Activate PPARα** (peroxisome proliferator-activated receptor alpha)
- ↑Lipoprotein lipase (LPL) → ↑TG hydrolysis
- ↑Fatty acid oxidation
- ↓VLDL production
- **Primary effect: ↓Triglycerides (30-50%)**
- **Secondary: ↑HDL (10-20%), variable LDL effect**

### Drug Examples

- **Fenofibrate**: Most commonly used
- **Gemfibrozil**: Older, more drug interactions
- Bezafibrate, ciprofibrate (not available in US)

### Pharmacokinetics

**Fenofibrate**:
- Prodrug, converted to fenofibric acid
- Take with meals (↑absorption)
- Renal excretion
- Dose adjustment in renal impairment

**Gemfibrozil**:
- Hepatic metabolism
- Renal excretion
- BID dosing (30 min before meals)

### Clinical Indications

**Primary Indication**:
- **Severe hypertriglyceridemia** (TG >500 mg/dL)
  - Prevent pancreatitis
  - TG >1000 mg/dL: High pancreatitis risk

**Secondary**:
- Mixed dyslipidemia (high TG, low HDL)
- Familial dysbetalipoproteinemia (Type III)

**NOT for**:
- Primary LDL lowering (statins superior)
- Routine cardiovascular prevention (no mortality benefit proven)

### Efficacy

- **TG**: ↓30-50%
- **HDL**: ↑10-20%
- **LDL**: Variable (may ↑if high TG baseline)

**Cardiovascular Outcomes**:
- Mixed results; no consistent mortality benefit
- **ACCORD trial**: Fenofibrate + statin vs. statin alone in diabetes
  - No overall benefit
  - Possible benefit in subgroup: High TG (>204), low HDL (<34)

### Adverse Effects

**Common**:
- **GI upset**: Dyspepsia, abdominal pain
- **Cholelithiasis**: ↑Cholesterol in bile (↑gallstones)
- ↑Liver enzymes

**Serious**:
- **Myopathy**: Especially with statins
  - **Gemfibrozil + statin**: High risk (avoid)
  - **Fenofibrate + statin**: Lower risk (use if needed)
- **Rhabdomyolysis**: Rare but serious
- ↑Creatinine (usually reversible)

**Other**:
- ↑Homocysteine
- Rash
- Venous thromboembolism (rare)

### Drug Interactions

**Statins**:
- **Gemfibrozil**: Inhibits statin glucuronidation → ↑statin levels → ↑myopathy
  - **Avoid gemfibrozil + statin**
- **Fenofibrate**: Safer combination (use if fibrate + statin needed)

**Warfarin**:
- ↑INR (displaces from albumin, ↓metabolism)
- Monitor INR closely

### Contraindications

- Severe renal impairment (CrCl <30, fenofibrate)
- Severe hepatic disease
- Gallbladder disease
- Pregnancy, breastfeeding

### Monitoring

- Baseline: Lipids, LFTs, CK, creatinine
- Periodic: LFTs, creatinine
- If with statin: Monitor for myopathy symptoms

### Clinical Pearls

1. **Primary indication**: Severe hypertriglyceridemia (prevent pancreatitis)
2. **TG >1000 mg/dL**: Urgent treatment needed
3. **Fenofibrate preferred**: Over gemfibrozil (if with statin)
4. **No mortality benefit**: For routine CV prevention
5. **Gallstones**: Risk increased
6. **Pregnancy Category C**: Avoid

---

## Bile Acid Sequestrants (Resins)

### Mechanism of Action

- Bind bile acids in intestine → prevent reabsorption
- ↓Enterohepatic bile acid recirculation
- Liver ↑bile acid synthesis from cholesterol
- ↓Hepatic cholesterol → ↑LDL receptors
- **↓LDL-C 15-30%**

### Drug Examples

- **Cholestyramine** (Questran): Powder, unpleasant taste
- **Colesevelam** (Welchol): Tablet, better tolerated
- **Colestipol**: Powder or tablet

### Pharmacokinetics

- **NOT absorbed** (remain in GI tract)
- No systemic side effects
- Bulky, require large doses

### Clinical Indications

1. **Adjunct to statin** (additional LDL lowering)
2. **Statin intolerance**
3. **Pregnancy** (safe, not absorbed)
4. **Children with FH**
5. **Type 2 diabetes** (colesevelam: ↓glucose)

### Efficacy

- **LDL**: ↓15-30%
- **TG**: May ↑10-20% (contraindicated if TG >300)
- **HDL**: Minimal change or slight ↑

**Cardiovascular Outcomes**:
- Older trials showed ↓CV events
- Not commonly used now (poorly tolerated)

### Adverse Effects

**GI** (very common):
- **Constipation** (most common)
- Bloating, flatulence
- Nausea
- Abdominal discomfort
- Poor palatability (powders)

**Metabolic**:
- ↑Triglycerides (activate VLDL synthesis)
- Interfere with fat-soluble vitamin absorption (A, D, E, K)

### Drug Interactions

**Absorption interference** (bind many drugs):
- Warfarin
- Digoxin
- Levothyroxine
- Thiazides
- Many others

**Strategy**: Take other drugs **1 hour before or 4 hours after** resin

### Contraindications

- Triglycerides >300-400 mg/dL
- Bowel obstruction
- Hypertriglyceridemia-induced pancreatitis

### Clinical Pearls

1. **Safe in pregnancy**: Only lipid-lowering drug (not absorbed)
2. **Poorly tolerated**: GI side effects limit use
3. **Drug interactions**: Dose other medications separately
4. **Colesevelam best tolerated**: Tablet form
5. **↑TG risk**: Monitor triglycerides
6. **Rarely used now**: Better alternatives available

---

## Niacin (Nicotinic Acid, Vitamin B3)

### Mechanism of Action

- Inhibits lipolysis in adipose tissue → ↓free fatty acids to liver
- ↓Hepatic VLDL synthesis → ↓LDL, ↓TG
- ↓Hepatic clearance of HDL-apoA1 → ↑HDL
- **Broad lipid effects**:
  - ↓LDL-C: 10-25%
  - ↓TG: 20-50%
  - **↑HDL-C: 15-35%** (most effective HDL-raising drug)
  - ↓Lp(a): 20-30%

### Formulations

- **Immediate-release** (IR): TID, more flushing
- **Extended-release** (ER): Daily, better tolerated
- **Sustained-release** (SR): Avoid (↑hepatotoxicity)

### Clinical Indications

**Previously Used**:
- Mixed dyslipidemia
- Low HDL
- Elevated Lp(a)

**Current Status**:
- **No longer recommended** for routine use
- **No cardiovascular benefit** in outcome trials when added to statin
- Adverse effects outweigh benefits

### Efficacy

**AIM-HIGH and HPS2-THRIVE Trials**:
- Niacin + statin vs. statin alone
- **No reduction in CV events**
- ↑Adverse effects
- Questioned utility of raising HDL pharmacologically

### Adverse Effects

**Cutaneous Flushing** (most common):
- Prostaglandin-mediated
- Occurs in 50-70%
- Reduces over time but often persists
- **Mitigation**: Aspirin 325 mg 30 min before dose, take with meals, gradual titration

**Hyperglycemia**:
- Worsens glucose control in diabetics
- May precipitate diabetes

**Hepatotoxicity**:
- ↑Transaminases (especially SR formulations)
- Monitor LFTs

**Hyperuricemia/Gout**:
- ↓Renal uric acid excretion
- May precipitate gout

**GI upset**:
- Dyspepsia, nausea, diarrhea

**Other**:
- Acanthosis nigricans
- Atrial fibrillation (rare)
- Macular edema

### Contraindications

- Active liver disease
- Active peptic ulcer disease
- Arterial bleeding
- Pregnancy

### Clinical Pearls

1. **No longer recommended**: Outcome trials showed no benefit
2. **Best HDL-raising drug**: But raising HDL doesn't reduce events
3. **Flushing**: Major tolerability issue
4. **Avoid SR formulation**: ↑Hepatotoxicity
5. **Historical importance**: Once popular, now obsolete for routine use

---

## Omega-3 Fatty Acids

### Mechanism of Action

- **EPA (eicosapentaenoic acid)** and **DHA (docosahexaenoic acid)**
- ↓Hepatic VLDL synthesis
- ↑Lipoprotein lipase activity
- **Primary effect: ↓Triglycerides (20-50%)**
- Slight ↑LDL (5-10%)
- Variable HDL effect

### Formulations

**Prescription**:
- **Icosapent ethyl** (Vascepa): Pure EPA, 4 g daily
- **Omega-3-acid ethyl esters** (Lovaza): EPA + DHA, 4 g daily

**Over-the-Counter**:
- Fish oil supplements (variable EPA/DHA content, not FDA regulated)

### Clinical Indications

**FDA-Approved**:
- Severe hypertriglyceridemia (TG >500 mg/dL)

**REDUCE-IT Trial** (Icosapent Ethyl):
- High-risk patients on statins with TG 135-499 mg/dL
- **↓CV events by 25%** (impressive)
- Suggests benefit beyond TG lowering

### Efficacy

- **TG**: ↓20-50% (dose-dependent)
- **LDL**: May ↑5-10%
- **HDL**: Minimal change

**REDUCE-IT**:
- Icosapent ethyl 4 g daily
- ↓CV death, MI, stroke, revascularization by 25%
- ↑Atrial fibrillation risk

### Adverse Effects

- **Fishy aftertaste, belching**
- GI upset
- **Atrial fibrillation** (REDUCE-IT trial)
- **Bleeding risk** (slight increase, antiplatelet effect)
- ↑LDL (especially with mixed EPA/DHA)

### Drug Interactions

- Anticoagulants/antiplatelets: Additive bleeding risk (monitor)

### Dosing

- **TG lowering**: 2-4 g daily of EPA + DHA
- **REDUCE-IT regimen**: Icosapent ethyl 2 g BID

### Clinical Pearls

1. **REDUCE-IT trial**: Changed practice; icosapent ethyl ↓CV events
2. **Pure EPA** (icosapent ethyl) preferred over EPA + DHA
3. **High-dose required**: 4 g daily for CV benefit
4. **Well-tolerated**: Minimal side effects
5. **OTC fish oil**: Variable quality, not equivalent to prescription

---

## Bempedoic Acid

### Mechanism of Action

- Inhibits **ATP citrate lyase** (upstream of HMG-CoA reductase in cholesterol synthesis)
- **Prodrug**: Activated in liver (not muscle)
- ↓Hepatic cholesterol synthesis → ↑LDL receptors
- **↓LDL-C ~15-25%**

### Clinical Indications

**FDA-Approved** (2020):
- Adjunct to diet and maximally tolerated statin in:
  - Heterozygous familial hypercholesterolemia OR
  - Established ASCVD requiring additional LDL lowering

**Key Use**: **Statin intolerance** (muscle-related)

### Efficacy

- **LDL**: ↓15-25%
- **With Ezetimibe**: Additive effect
- **With Statin**: Additive effect

**Cardiovascular Outcomes**:
- Ongoing trials (results pending)

### Adverse Effects

- **Hyperuricemia/Gout**: ↓Renal uric acid excretion
- Tendon rupture (rare)
- ↑Creatinine (small, reversible)
- ↑Liver enzymes (rare)
- **Less myopathy than statins** (not activated in muscle)

### Dosing

- 180 mg PO daily

### Clinical Pearls

1. **Statin alternative**: For statin-intolerant patients
2. **No muscle activation**: Prodrug activated in liver only
3. **Gout risk**: Monitor uric acid
4. **Modest LDL reduction**: 15-25%
5. **Fixed-dose combination**: Bempedoic acid + ezetimibe available

---

## Emerging Therapies

### Inclisiran

- **siRNA** (small interfering RNA) targeting PCSK9
- Inhibits hepatic PCSK9 synthesis
- **Twice-yearly injection** (major advantage)
- ↓LDL-C ~50%
- FDA-approved 2021
- Expensive, limited availability

### Lomitapide, Mipomersen

- For **homozygous familial hypercholesterolemia**
- Very rare indication
- Significant side effects
- Restricted distribution

---

## Treatment Approach

### 2018 ACC/AHA Cholesterol Guidelines

**Risk-Based Approach**:

**Very High Risk** (secondary prevention + multiple events):
- High-intensity statin
- If LDL ≥70 on max statin: Add ezetimibe
- If LDL ≥70 on max statin + ezetimibe: Add PCSK9 inhibitor

**High Risk** (ASCVD):
- High-intensity statin
- Goal: ↓LDL ≥50%

**Moderate Risk** (diabetes, 10-year ASCVD risk 7.5-20%):
- Moderate- to high-intensity statin

**Borderline/Low Risk**:
- Consider moderate-intensity statin if risk enhancers present

### Statin Intolerance

**Approach**:
1. Try different statin (atorvastatin, rosuvastatin often better tolerated)
2. Lower dose or alternate-day dosing
3. Alternative agents:
   - Ezetimibe
   - Bempedoic acid
   - PCSK9 inhibitor
   - Bile acid sequestrant (if no TG elevation)

### Severe Hypertriglyceridemia (>500 mg/dL)

**Approach**:
1. **Lifestyle**: Weight loss, low-fat diet, ↓alcohol, ↓simple carbs
2. **Fibrate** (fenofibrate)
3. **Omega-3 fatty acids** (high-dose)
4. **Avoid**: Estrogen, β-blockers, thiazides (worsen TG)
5. If TG >1000: **Urgent treatment** (pancreatitis risk)

---

## Clinical Pearls - Summary

1. **Statins**: First-line for ASCVD prevention, proven mortality benefit
2. **Ezetimibe**: Add to statin for additional LDL lowering
3. **PCSK9 inhibitors**: Most potent LDL lowering; very expensive
4. **Fibrates**: For severe hypertriglyceridemia (prevent pancreatitis)
5. **Niacin**: No longer recommended (no CV benefit in trials)
6. **Icosapent ethyl**: ↓CV events in REDUCE-IT trial
7. **Bempedoic acid**: Alternative in statin intolerance
8. **Risk-based approach**: Statin intensity based on ASCVD risk
9. **LDL reduction**: Each 40 mg/dL ↓ → ~20% ↓CV events
10. **Combination therapy**: Statin + ezetimibe ± PCSK9 inhibitor for high-risk patients

---

## Key Takeaways

1. **Statins** are first-line for lipid lowering and CV risk reduction
2. **High-intensity statins** for secondary prevention (ASCVD)
3. **Ezetimibe** added to statins for additional LDL lowering
4. **PCSK9 inhibitors** reserved for very high-risk patients on max therapy
5. **Fibrates** primarily for severe hypertriglyceridemia
6. **Icosapent ethyl** reduces CV events in high-risk patients
7. **Myopathy** is the main concern with statins; rhabdomyolysis rare
8. **Drug interactions** important, especially with CYP3A4 inhibitors
9. **Statin intolerance**: Try alternative statins or non-statin agents
10. **Benefits of LDL lowering**: Well-established for CV event reduction

---

## References

1. Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019.
2. Katzung's Basic & Clinical Pharmacology, 15th Edition
3. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
4. Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). NEJM 2019.
5. Sabatine MS, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER). NEJM 2017.
6. Cannon CP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (IMPROVE-IT). NEJM 2015.
